The Management of Psychiatric Disorders During and After Pregnancy-Presentation Slides

Presentation Slides

Pdf Summary

The APA and SAMHSA, through the Clinical Support System for Serious Mental Illness (CSS-SMI), present guidelines for managing psychiatric disorders during and after pregnancy. This initiative includes offering continuing education credits for healthcare professionals. The webinar, hosted by Dr. Jennifer L. Payne, Vice Chair of Research in the Department of Psychiatry at the University of Virginia, addresses the importance of treating psychiatric illnesses during the perinatal period for both maternal and infant health outcomes.<br /><br />Key Learning Objectives:<br />- Identifying risks of untreated depression during pregnancy.<br />- Defining “confounding by indication.”<br />- Listing psychiatric medications contraindicated during pregnancy.<br />- Explaining the action mechanism of new FDA-approved postpartum depression medications like brexanolone and zuranolone.<br /><br />The webinar discusses the critical reasons for treating perinatal psychiatric illnesses, including increased maternal mortality rates and negative outcomes like preterm birth, low birth weight, and increased risk of postpartum depression. Specific rules for medication management during pregnancy and lactation emphasize cautious use, stability before and during pregnancy, monitoring blood levels, and avoiding multiple medications.<br /><br />Brexanolone and zuranolone are highlighted as new, FDA-approved treatments for postpartum depression that act on GABA-A receptors. Brexanolone is administrated intravenously and requires participation in a Risk Evaluation and Mitigation Strategy (REMS) program due to risks like excessive sedation. It's rapidly effective and offers sustained benefits. Zuranolone, taken orally, shows promise in both major and postpartum depression treatment, with a rapid and sustained response noted.<br /><br />The webinar concludes with considerations on selecting appropriate treatment options, emphasizing planning, and the individualized approach for managing maternal mental health. The initiative encourages the use of the SMI Adviser mobile app for further support and resources.

Keywords

psychiatric disorders

pregnancy

perinatal period

maternal health

infant health

depression

psychiatric medications

brexanolone

zuranolone

mental health treatment